journal

Lancet Neurology

journal
https://read.qxmd.com/read/32622375/neurological-associations-of-covid-19
#1
REVIEW
Mark A Ellul, Laura Benjamin, Bhagteshwar Singh, Suzannah Lant, Benedict Daniel Michael, Ava Easton, Rachel Kneen, Sylviane Defres, Jim Sejvar, Tom Solomon
BACKGROUND: The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is of a scale not seen since the 1918 influenza pandemic. Although the predominant clinical presentation is with respiratory disease, neurological manifestations are being recognised increasingly. On the basis of knowledge of other coronaviruses, especially those that caused the severe acute respiratory syndrome and Middle East respiratory syndrome epidemics, cases of CNS and peripheral nervous system disease caused by SARS-CoV-2 might be expected to be rare...
July 2, 2020: Lancet Neurology
https://read.qxmd.com/read/32473659/correction-to-lancet-neurol-2020-19-481-82
#2
(no author information available yet)
No abstract text is available yet for this article.
May 28, 2020: Lancet Neurology
https://read.qxmd.com/read/32464102/health-care-for-chronic-neurological-patients-after-covid-19
#3
Angelo Antonini
No abstract text is available yet for this article.
May 22, 2020: Lancet Neurology
https://read.qxmd.com/read/32464101/integrated-and-patient-centred-management-of-parkinson-s-disease-a-network-model-for-reshaping-chronic-neurological-care
#4
REVIEW
Bastiaan R Bloem, Emily J Henderson, E Ray Dorsey, Michael S Okun, Njideka Okubadejo, Piu Chan, John Andrejack, Sirwan K L Darweesh, Marten Munneke
Chronic neurological diseases are the leading cause of disability globally. Yet, our health-care systems are not designed to meet the needs of many patients with chronic neurological conditions. Care is fragmented with poor interdisciplinary collaboration and lack of timely access to services and therapies. Furthermore, care is typically reactive, and complex problems are managed inadequately because of a scarcity of disease-specific expertise and insufficient use of non-pharmacological interventions. Treatment plans tend to focus on the disease rather than the individual living with it, and patients are often not involved in clinical decision making...
May 22, 2020: Lancet Neurology
https://read.qxmd.com/read/32445622/understanding-multifactorial-brain-changes-in-type-2-diabetes-a-biomarker-perspective
#5
REVIEW
Geert Jan Biessels, Flavio Nobili, Charlotte E Teunissen, Rafael Simó, Philip Scheltens
People with type 2 diabetes are at an increased risk of cognitive impairment and dementia (including Alzheimer's disease), as well as subtle forms of cognitive dysfunction. Current diabetes guidelines recommend screening for cognitive impairment in groups at high risk and providing guidance for diabetes management in patients with diabetes and cognitive impairment. Yet, no disease-modifying treatment is available and important questions remain about the mechanisms underlying diabetes-associated cognitive dysfunction...
May 20, 2020: Lancet Neurology
https://read.qxmd.com/read/32445621/interrelationships-among-central-insulin-signalling-diabetes-and-cognitive-impairment
#6
Lenore J Launer
No abstract text is available yet for this article.
May 20, 2020: Lancet Neurology
https://read.qxmd.com/read/32359409/an-italian-programme-for-covid-19-infection-in-multiple-sclerosis
#7
LETTER
Maria Pia Sormani
No abstract text is available yet for this article.
April 30, 2020: Lancet Neurology
https://read.qxmd.com/read/32562687/correction-to-lancet-neurol-2019-18-942-52
#8
(no author information available yet)
No abstract text is available yet for this article.
July 2020: Lancet Neurology
https://read.qxmd.com/read/32562686/brain-injury-after-cardiac-arrest-from-prognostication-of-comatose-patients-to-rehabilitation
#9
REVIEW
Tobias Cronberg, David M Greer, Gisela Lilja, Véronique Moulaert, Paul Swindell, Andrea O Rossetti
More patients are surviving cardiac arrest than ever before; however, the burden now lies with estimating neurological prognoses in a large number of patients who were initially comatose, in whom the ultimate outcome is unclear. Neurologists, neurointensivists, and clinical neurophysiologists must accurately balance the concern that overly conservative prognostication could leave patients in a severely disabled state, with the possibility that inaccurately pessimistic prognostication could lead to the withdrawal of life-sustaining treatment in patients who might otherwise have a good functional outcome...
July 2020: Lancet Neurology
https://read.qxmd.com/read/32562685/prehospital-stroke-management-in-the-thrombectomy-era
#10
REVIEW
Klaus Fassbender, Silke Walter, Iris Q Grunwald, Fatma Merzou, Shrey Mathur, Martin Lesmeister, Yang Liu, Thomas Bertsch, James C Grotta
Acute stroke management has been revolutionised by evidence of the effectiveness of thrombectomy. Because time is brain in stroke care, the speed with which a patient with large vessel occlusion is transferred to a thrombectomy-capable centre determines outcome. Therefore, each link in the stroke rescue chain, starting with symptom onset and ending with recanalisation, should be streamlined. However, in contrast to inhospital delays, prehospital delays are unchanged despite substantial efforts in quality improvement...
July 2020: Lancet Neurology
https://read.qxmd.com/read/32562684/safety-and-immunogenicity-of-the-%C3%AE-synuclein-active-immunotherapeutic-pd01a-in-patients-with-parkinson-s-disease-a-randomised-single-blinded-phase-1-trial
#11
Dieter Volc, Werner Poewe, Alexandra Kutzelnigg, Petra Lührs, Caroline Thun-Hohenstein, Achim Schneeberger, Gergana Galabova, Nour Majbour, Nishant Vaikath, Omar El-Agnaf, Dorian Winter, Eva Mihailovska, Andreas Mairhofer, Carsten Schwenke, Günther Staffler, Rossella Medori
BACKGROUND: Robust evidence supports the role of α-synuclein pathology as a driver of neuronal dysfunction in Parkinson's disease. PD01A is a specific active immunotherapy with a short peptide formulation targeted against oligomeric α-synuclein. This phase 1 study assessed the safety and tolerability of the PD01A immunotherapeutic in patients with Parkinson's disease. METHODS: We did a first-in-human, randomised, phase 1 study of immunisations with PD01A, followed by three consecutive study extensions...
July 2020: Lancet Neurology
https://read.qxmd.com/read/32562683/effect-of-dulaglutide-on-cognitive-impairment-in-type-2-diabetes-an-exploratory-analysis-of-the-rewind-trial
#12
Tali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, Rafael Diaz, Luis-Emilio García-Pérez, Mark Lakshmanan, Angelyn Bethel, Denis Xavier, Jeffrey Probstfield, Matthew C Riddle, Lars Rydén, Charles Messan Atisso, Stephanie Hall, Purnima Rao-Melacini, Jan Basile, William C Cushman, Edward Franek, Matyas Keltai, Fernando Lanas, Lawrence A Leiter, Patricio Lopez-Jaramillo, Valdis Pirags, Nana Pogosova, Peter J Raubenheimer, Jonathan E Shaw, Wayne H-H Sheu, Theodora Temelkova-Kurktschiev
BACKGROUND: Diabetes is an independent risk factor for cognitive impairment. We aimed to investigate the association between the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide and cognitive impairment as an exploratory analysis within the Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial. METHODS: REWIND is a randomised, double-blind placebo-controlled trial at 371 sites in 24 countries. We included men and women (aged ≥50 years) with either established or newly diagnosed type 2 diabetes and additional cardiovascular risk factors, glycated haemoglobin of up to 9·5% (80 mmol/mol) on a maximum of two oral glucose-lowering drugs with or without basal insulin, and a body-mass index of at least 23 kg/m2 ...
July 2020: Lancet Neurology
https://read.qxmd.com/read/32562682/medical-management-with-interventional-therapy-versus-medical-management-alone-for-unruptured-brain-arteriovenous-malformations-aruba-final-follow-up-of-a-multicentre-non-blinded-randomised-controlled-trial
#13
Jay P Mohr, Jessica R Overbey, Andreas Hartmann, Rüdiger von Kummer, Rustam Al-Shahi Salman, Helen Kim, H Bart van der Worp, Michael K Parides, Marco A Stefani, Emmanuel Houdart, Richard Libman, John Pile-Spellman, Kirsty Harkness, Charlotte Cordonnier, Ellen Moquete, Alessandra Biondi, Catharina J M Klijn, Christian Stapf, Alan J Moskowitz
BACKGROUND: In A Randomized trial of Unruptured Brain Arteriovenous malformations (ARUBA), randomisation was halted at a mean follow-up of 33·3 months after a prespecified interim analysis showed that medical management alone was superior to the combination of medical management and interventional therapy in preventing symptomatic stroke or death. We aimed to study whether these differences persisted through 5-years' follow-up. METHODS: ARUBA was a non-blinded, randomised trial done at 39 clinical centres in nine countries...
July 2020: Lancet Neurology
https://read.qxmd.com/read/32562681/marten-munneke
#14
(no author information available yet)
No abstract text is available yet for this article.
July 2020: Lancet Neurology
https://read.qxmd.com/read/32562680/covid-19-can-we-learn-from-encephalitis-lethargica
#15
REVIEW
Antonino Giordano, Ghil Schwarz, Laura Cacciaguerra, Federica Esposito, Massimo Filippi
No abstract text is available yet for this article.
July 2020: Lancet Neurology
https://read.qxmd.com/read/32562679/clifford-saper-preeminent-sleep-scientist-and-private-novelist
#16
Ruth Williamson
No abstract text is available yet for this article.
July 2020: Lancet Neurology
https://read.qxmd.com/read/32562678/health-inequalities-in-stroke-and-dementia-prevention
#17
LETTER
Carol Brayne
No abstract text is available yet for this article.
July 2020: Lancet Neurology
https://read.qxmd.com/read/32562677/attention-in-subjective-cognitive-decline-authors-reply
#18
LETTER
Frank Jessen
No abstract text is available yet for this article.
July 2020: Lancet Neurology
https://read.qxmd.com/read/32562676/attention-in-subjective-cognitive-decline
#19
LETTER
Linpei Jia, Hongliang Zhang
No abstract text is available yet for this article.
July 2020: Lancet Neurology
https://read.qxmd.com/read/32562675/factors-affecting-relapse-rate-in-patients-with-neuromyelitis-optica-spectrum-disorder-authors-reply
#20
LETTER
Masayuki Tahara, Tomoko Oeda, Hideyuki Sawada
No abstract text is available yet for this article.
July 2020: Lancet Neurology
journal
journal
20188
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"